title: The impact of hypertriglyceridemia on prostate cancer development in patients aged ≥60 years.
abstract: OBJECTIVE
  •  To investigate the relationship between serum triglyceride (TG) levels and the incidence and characteristics of prostate cancer detected on biopsy.
  
  
  METHODS
  •  We evaluated data from consecutive patients who underwent prostatic biopsy. Data analysed included age, total serum prostate-specific antigen (PSA) level, prostatic volume, body mass index (BMI), TG levels, and cholesterol-lowering medications.
  
  
  RESULTS
  •  We analysed data from 905 patients, including 528 (58.3%) with positive biopsy findings. •  Using 150 mg/dL as the threshold point of TG levels, multivariate analysis yielded an adjusted odds ratio (OR) reflecting the association of higher TG levels with prostate cancer diagnosis of 1.66 (95% confidence interval (CI) 1.21-2.29, P = 0.002). •  Pearson correlation coefficient analysis including age, PSA level, prostatic volume, BMI and TG, showed TG level significantly correlated with BMI (r = 0.185, P < 0.001). •  In the analysis by age intervals (≤59, 60-69, and ≥70 years), the association between high TG levels and positive biopsy findings was enhanced in the age groups 60-69 and ≥70 years (OR 2.10, 95% CI 1.31-3.37, P = 0.002 and OR 1.91, 95% CI 1.03-3.53, P = 0.039, respectively), but not in the group aged ≤59 years. •  In patients aged ≥60 years, high TG levels were statistically significantly associated with a Gleason score of ≥8.
  
  
  CONCLUSIONS
  •  High TG levels correlated well with a higher incidence of prostate cancer, especially in patients aged ≥60 years. •  High TG levels were also associated with a Gleason score of ≥8 in this age group. •  Our results suggest that elderly patients with high TG levels may be more vulnerable to the development of prostate cancer with an aggressive biology.
authors.affiliation: Department of Urology, Division of Clinical Research and Development, Jikei University School of Medicine, Minato-ku, Tokyo, Japan. nhurology@yahoo.co.jp
authors.forename: Norihiro
authors.initials: N
authors.lastname: Hayashi
authors.forename: Masato
authors.initials: M
authors.lastname: Matsushima
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sasaki
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Takahashi
authors.forename: Shin
authors.initials: S
authors.lastname: Egawa
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001706:Biopsy; D015992:Body Mass Index; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D015228:Hypertriglyceridemia / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009929:Organ Size; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000209:etiology* / Q000473:pathology; D012307:Risk Factors
chemical_list: D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017430:Prostate-Specific Antigen